Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
Want to see ARTV full AI Analyst Report?
Top Page
Artiva Biotherapeutics, Inc.
(NASDAQ:ARTV)
Select Model
Select Model
Rating:45Neutral
Price Target:
$7.50
▼(-40.24% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by weak financial performance (continued losses, minimal/absent recent revenue, and heavy cash burn), with only partial support from a manageable debt profile. Technicals add a mild negative bias due to weaker near-term trend and subdued momentum, while valuation provides little support because the company is loss-making and offers no dividend. Corporate updates are constructive on the pipeline and financing runway but are tempered by dilution from the large equity raise.
Positive Factors
Robust AlloNK clinical efficacy and FDA Phase 3 alignment
Demonstrated high response rates and favorable tolerability materially improve the probability of a successful registrational program. FDA alignment on a single Phase 3 reduces regulatory uncertainty and concentrates resources, strengthening the long-term path to approval and commercialization in autoimmune indications.
Negative Factors
Sustained, large cash burn
Persistent negative operating and free cash flow indicate the business is consuming material cash to advance trials. This ongoing burn necessitates frequent external funding, raises dilution risk, and places execution contingent on successful capital raises or partnerships over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust AlloNK clinical efficacy and FDA Phase 3 alignment
Demonstrated high response rates and favorable tolerability materially improve the probability of a successful registrational program. FDA alignment on a single Phase 3 reduces regulatory uncertainty and concentrates resources, strengthening the long-term path to approval and commercialization in autoimmune indications.
Read all positive factors
Artiva Biotherapeutics, Inc. (ARTV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$193.78M
Dividend YieldN/A
Average Volume (3M)565.67K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue GrowthN/A
EPS Growth-18.99%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.55
Shares Outstanding24,716,673
10 Day Avg. Volume987,009
30 Day Avg. Volume565,672
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-280.47
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$35.00Price Target Upside178.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.63
Revenue Forecast (FY)N/A
Artiva Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an of...
How the Company Makes Money
As a clinical-stage biotechnology company, Artiva Biotherapeutics does not have publicly available information in this context confirming product sales as a recurring revenue source; accordingly, product-revenue details are null. Typical monetizat...
Artiva Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 251.00K | 33.49M | 4.93M | 2.00M |
| Gross Profit | -666.00K | -2.60M | 251.00K | 33.49M | 4.93M | 2.00M |
| EBITDA | -89.43M | -88.01M | -64.85M | -28.41M | -58.67M | -71.58M |
| Net Income | -87.07M | -83.86M | -58.49M | -27.70M | -58.39M | -71.83M |
Balance Sheet | ||||||
| Total Assets | 105.95M | 130.94M | 209.58M | 105.11M | 133.05M | 169.93M |
| Cash, Cash Equivalents and Short-Term Investments | 86.78M | 108.01M | 185.43M | 76.97M | 102.53M | 160.92M |
| Total Debt | 10.26M | 10.94M | 14.35M | 16.91M | 19.45M | 1.74M |
| Total Liabilities | 18.11M | 20.97M | 22.94M | 267.13M | 273.75M | 258.78M |
| Stockholders Equity | 87.85M | 109.97M | 186.64M | -162.01M | -140.70M | -88.86M |
Cash Flow | ||||||
| Free Cash Flow | -80.18M | -79.34M | -55.67M | -50.69M | -57.13M | -17.03M |
| Operating Cash Flow | -77.86M | -76.75M | -55.03M | -47.43M | -50.83M | -15.30M |
| Investing Cash Flow | 68.76M | 63.41M | -120.46M | -25.98M | -6.30M | -1.72M |
| Financing Cash Flow | -342.00K | 9.00K | 162.23M | 24.39M | -1.26M | 152.75M |
Artiva Biotherapeutics, Inc. Technical Analysis
Neutral
12.55
Price Trends
8.55
Negative
6.59
Positive
4.98
Positive
Market Momentum
0.04
Positive
39.12
Neutral
4.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Neutral. The current price of 12.55 is above the 20-day moving average (MA) of 10.33, above the 50-day MA of 8.55, and above the 200-day MA of 4.98, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 39.12 is Neutral, neither overbought nor oversold. The STOCH value of 4.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARTV.
Artiva Biotherapeutics, Inc. Risk Analysis
Artiva Biotherapeutics, Inc. disclosed 91 risk factors in its most recent earnings report. Artiva Biotherapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artiva Biotherapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $72.54M | ― | -80.35% | ― | ― | 27.27% | |
45 Neutral | $193.78M | ― | -73.16% | ― | ― | -18.99% | |
45 Neutral | $24.42M | -3.58 | -191.12% | ― | ― | 38.53% | |
44 Neutral | $74.30M | -0.97 | -59.06% | ― | ― | 49.00% | |
43 Neutral | $28.60M | -47.59 | -88.89% | ― | -100.00% | -170.04% |
* Healthcare Sector Average
ARTV
Artiva Biotherapeutics, Inc.
7.99
6.01
303.54%
ACET
Adicet Bio
7.89
-3.61
-31.39%
ABVC
ABVC BioPharma
1.11
-0.10
-8.26%
JSPR
Jasper Therapeutics
0.87
-4.00
-82.09%
PLRX
Pliant Therapeutics
1.23
-0.11
-8.21%
Artiva Biotherapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Artiva Biotherapeutics Announces Major Executive Leadership Transitions
Neutral
May 19, 2026
On May 18, 2026, Artiva Biotherapeutics announced several leadership changes, including the resignation of board member Diego Miralles, M.D., who left the Board to assume the role of President and Head of Research and Development, reducing the Boa...
Private Placements and FinancingRegulatory Filings and Compliance
Artiva Biotherapeutics Announces $300 Million Equity Offering
Positive
May 8, 2026
On May 8, 2026, Artiva Biotherapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to issue 23,871,526 shares of common stock at $11.52 per share. The company also agreed to sell pre-funded warrants to purchas...
Business Operations and StrategyFinancial Disclosures
Artiva Highlights AlloNK RA Data and Phase 3 Alignment
Positive
May 8, 2026
Artiva Biotherapeutics reported first-quarter 2026 results on May 8, 2026, alongside initial clinical data showing strong efficacy and favorable tolerability for its lead NK cell therapy AlloNK in refractory rheumatoid arthritis and other B-cell-d...
Business Operations and StrategyExecutive/Board Changes
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer
Positive
Feb 24, 2026
Artiva Biotherapeutics announced on February 24, 2026 that its board appointed veteran finance executive Thad Huston as chief financial officer, effective February 18, 2026, making him the company’s principal financial and accounting officer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.